Bellevue Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$8.32M Sell
151,445
-216,928
-59% -$11.9M 0.18% 69
2025
Q1
$26M Buy
368,373
+39,352
+12% +$2.78M 0.58% 39
2024
Q4
$21.6M Sell
329,021
-1,955
-0.6% -$129K 0.42% 59
2024
Q3
$23.3M Buy
330,976
+278,744
+534% +$19.6M 0.38% 69
2024
Q2
$4.3M Sell
52,232
-269,555
-84% -$22.2M 0.07% 98
2024
Q1
$28.1M Sell
321,787
-3,989
-1% -$348K 0.43% 66
2023
Q4
$31.4M Sell
325,776
-24,112
-7% -$2.32M 0.48% 63
2023
Q3
$31M Sell
349,888
-10,716
-3% -$948K 0.5% 55
2023
Q2
$31.3M Buy
360,604
+312,159
+644% +$27.1M 0.45% 65
2023
Q1
$4.71M Sell
48,445
-12,240
-20% -$1.19M 0.07% 105
2022
Q4
$6.28M Buy
60,685
+7,192
+13% +$744K 0.08% 107
2022
Q3
$4.54M Sell
53,493
-20,260
-27% -$1.72M 0.07% 111
2022
Q2
$6.11M Sell
73,753
-847
-1% -$70.2K 0.09% 110
2022
Q1
$5.75M Buy
74,600
+3,200
+4% +$247K 0.07% 114
2021
Q4
$6.31M Buy
71,400
+19,700
+38% +$1.74M 0.07% 120
2021
Q3
$4M Buy
51,700
+11,200
+28% +$866K 0.04% 136
2021
Q2
$3.38M Buy
40,500
+3,500
+9% +$292K 0.03% 137
2021
Q1
$2.79M Buy
+37,000
New +$2.79M 0.03% 134
2020
Q3
Sell
-76,900
Closed -$9.49M 218
2020
Q2
$9.49M Buy
76,900
+4,800
+7% +$592K 0.13% 109
2020
Q1
$6.09M Buy
72,100
+4,900
+7% +$414K 0.12% 110
2019
Q4
$5.68M Buy
+67,200
New +$5.68M 0.09% 110
2019
Q1
Sell
-45,969
Closed -$3.91M 137
2018
Q4
$3.91M Sell
45,969
-1,900
-4% -$162K 0.26% 76
2018
Q3
$4.64M Sell
47,869
-1,650
-3% -$160K 0.29% 74
2018
Q2
$4.67M Buy
49,519
+5,169
+12% +$487K 0.4% 56
2018
Q1
$3.6M Sell
44,350
-700
-2% -$56.7K 0.36% 58
2017
Q4
$4.02M Sell
45,050
-3,750
-8% -$334K 0.42% 53
2017
Q3
$4.54M Sell
48,800
-16,200
-25% -$1.51M 0.48% 56
2017
Q2
$5.9M Hold
65,000
0.7% 53
2017
Q1
$5.71M Hold
65,000
0.76% 46
2016
Q4
$5.39M Hold
65,000
1.1% 30
2016
Q3
$6.01M Hold
65,000
1.09% 34
2016
Q2
$5.06M Hold
65,000
0.95% 38
2016
Q1
$5.36M Buy
+65,000
New +$5.36M 0.97% 36